sales@intentmarketresearch.com
+1 463-583-2713
According to Intent Market Research, the RNA Analysis Market is expected to grow from USD 5.5 billion in 2023-e at a CAGR of 10.8% to touch USD 10.3 billion by 2030. The RNA analysis market is competitive, the prominent players in the global market include Agilent, Basepair, BioMérieux, Bio-Rad Laboratories, Eurofins, GenXPro, Illumina, Promega Corporation, Qiagen, Roche, Thermo Fisher Scientific, amongst others. The market is thriving due to the rising interest for personalized medicines across the globe.
Click here to: Get FREE Sample Pages of this Report
The emergence of the COVID-19 pandemic significantly influenced the market, with a surge in demand for testing and diagnosis due to the severity of the SARS-CoV-2 virus infection. The pandemic prompted increased research to unravel the virus's genetic makeup, driving demand for next-generation sequencing (NGS) and polymerase chain reaction (PCR). While the initial impact was favorable, with heightened market activity during the pandemic, the current post-pandemic phase has led to a slight loss of momentum.
The RNA analysis market is experiencing a surge in interest due to the growing demand for personalized medicine. This is accompanied by increased investments in pharmaceutical and biotechnology research, emphasizing the industry's commitment to innovative healthcare solutions.
This segment involves the supply of chemical and biological substances essential for RNA analysis, including primers, probes, enzymes, and other consumables. The demand for reagents/consumables is directly correlated with the overall adoption and usage of RNA analysis technologies. As researchers and laboratories engage in RNA analysis processes, the consumption of reagents and consumables increases.
According to the World Health Organization's February 2022 update, cancer stands as a major global cause of mortality, with cancer-causing infections such as human papillomavirus (HPV) and hepatitis contributing to around 30% of cases in low- and lower-middle-income countries. Given the substantial burden of cancer and infectious diseases, there is an escalating demand for diagnosis in medical specialties and diagnostic care centres, projecting substantial growth for the reagents/consumables segment throughout the forecast period.
PCR is a fundamental technology in RNA analysis, facilitating the amplification of RNA sequences for further study. Advancements in PCR technology, such as the introduction of real-time PCR, contribute significantly to the evolution of this segment. Real-time PCR enables researchers to monitor the amplification process in real time, providing quantitative data and enhancing the precision of RNA analysis. The continuous improvement and innovation in PCR technology drive market growth by offering more efficient and accurate tools for RNA analysis applications.
RNA analysis is a cornerstone in drug discovery and development processes. It plays a pivotal role in identifying potential drug targets and understanding gene expression patterns associated with diseases. The pharmaceutical industry heavily relies on RNA analysis to discover new therapeutic targets, assess drug efficacy, and optimize treatment strategies. The demand for RNA analysis tools and services in the drug discovery and development segment is instrumental in shaping the market landscape.
The demand for RNA analysis tools and services is particularly high in the pharmaceutical and biotechnology sectors. These industries are at the forefront of drug development and research activities, relying on RNA analysis for various applications, including target identification, biomarker discovery, and understanding disease mechanisms.
The RNA analysis market in Europe experiences growth driven by active research, technological advancements in next-generation sequencing, government funding, collaborative efforts, and expanding clinical applications. Institutions and companies engage in RNA-related research, contributing to advancements in genomics and transcriptomics.
For instance, the market segment's growth is further propelled by strategic product launches from key players. For instance, in March 2021, PCR Biosystems, a UK-based company introduced the IsoFast BST Polymerase reagents range for rapid, robust, and sensitive RNA amplification. These product approvals are poised to significantly contribute to the segment's growth during the forecast period.
The market is characterized by intense competition due to the presence of numerous international and domestic players. The RNA analysis market, in particular, is dominated by key players such as Agilent, Basepair, BioMérieux, Bio-Rad Laboratories, Eurofins, GenXPro, Illumina, Promega Corporation, Qiagen, Roche, Thermo Fisher Scientific, amongst others.
The integration of personalized medicine into mainstream clinical practice has revolutionized disease detection, classification, and treatment. This paradigm shift is particularly evident in oncology, where tailored medications, therapies, and diagnostic tests have become more prevalent. As per the American Cancer Society, the increasing burden of cancer worldwide, with an estimated 29.0 million cases by 2040, contributes to the growing demand for RNA analysis products to develop innovative precision medicines for cancer.
Market players are actively contributing to growth through product developments and innovations. For instance, in April 2022, Lexogen's introduced CORALL RNA-Seq V2 whole transcriptome library prep kit, a cutting-edge technology enabling comprehensive RNA molecule determination in samples. Additionally, a strategic initiative in January 2021 by Merck acquired AmpTec to enhance mRNA development capabilities. Through the acquisition, Merck will be better equipped to research, develop, and produce mRNA for its clients' usage in COVID-19 and other disease-specific therapies, diagnostics, and vaccinations, which are anticipated to bolster market growth.
Click here to: Get your custom research report today
The report provides key insights into the RNA analysis market, and it focuses on technological developments, trends, and initiatives taken by the government in this sector. The report delves into market drivers, restraints, and opportunities, and analyses key players and the competitive landscape within the market. The report offers the market size and forecasts for the RNA analysis market in value (USD billion) for all the above segments.
Report Features |
Description |
Market Size (2023-e) |
USD 5.5 billion |
Forecast Revenue (2030) |
USD 10.3 billion |
CAGR (2024-2030) |
10.8% |
Base Year for Estimation |
2023-e |
Historic Year |
2022 |
Forecast Period |
2024-2030 |
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
Segments Covered |
By Product & Service (Reagents/Consumables, Instrument, Software, Services), By Technology (Polymerase Chain Reaction, Microarray, Sequencing, RNA Interference, Others), By Application (Drug Discovery & Development, Clinical Diagnostics, Toxicogenomics, Transcriptome Analysis, Others), By End-Use Industry (Pharmaceutical & Biotechnology Company, Hospitals & Diagnostic Centers, Academic & Research Institutes, Clinical Research Organization) |
Regional Analysis |
North America (US, Canada), Europe (Germany, France, UK, Spain, Italy), Asia-Pacific (China, Japan, South Korea, India), Latin America (Brazil, Mexico, Argentina), Middle East and Africa (Saudi Arabia, South Africa, Turkey, United Arab Emirates) |
Competitive Landscape |
Agilent, Basepair, BioMérieux, Bio-Rad Laboratories, Eurofins, GenXPro, Illumina, Promega Corporation, Qiagen, Roche, Thermo Fisher Scientific, amongst others |
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. |
Purchase Options |
We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) |
1.Introduction |
1.1.Study Assumptions and Market Definition |
1.2.Scope of the Study |
2.Research Methodology |
3.Executive Summary |
4.Market Dynamics |
4.1.Market Growth Drivers |
4.1.1.Growing Interest in Personalized Medicine |
4.1.2.Expanding Applications of RNA Sequencing |
4.1.3.Rising Investments in Pharmaceutical and Biotechnology |
4.2.Market Growth Restraints |
4.2.1.Data Analysis Challenges |
4.3.Market Growth Opportunities |
4.3.1.Promising Expansion Opportunities in Emerging Markets |
4.3.2.Growing Utilization in Toxicogenomics Applications |
4.4.Pestle Analysis |
4.5.Porter’s Five Forces Analysis |
5.Market Outlook |
5.1.Overview (Industry Snapshot) |
5.2.Technology Analysis |
5.3.Supply Chain Analysis |
5.4.Value Chain Analysis |
5.5.Regulatory Analysis |
5.6.Ecosystem Analysis |
5.7.Patent Analysis |
5.8.Trade Analysis |
5.9.Trends/Disruptions |
6.Market Segment Outlook (Market Size & Forecast: USD Billion, 2024 – 2030) |
6.1.Segment Synopsis |
6.2.By Product & Service |
6.2.1.Reagents/Consumables |
6.2.2.Instruments |
6.2.3.Software |
6.2.4.Services |
6.3.By Technology |
6.3.1.Polymerase Chain Reaction (PCR) |
6.3.2.Microarrays |
6.3.3.Sequencing |
6.3.4.RNA Interference |
6.3.5.Others |
6.4.By Application |
6.4.1.Drug Discovery & Development |
6.4.2.Toxicogenomics |
6.4.3.Clinical Diagnostics |
6.4.4.Transcriptome Analysis |
6.4.5.Others |
6.5.By End-Use |
6.5.1.Pharmaceutical Companies |
6.5.2.Hospitals & Diagnostic Centers |
6.5.3.Research Institutes |
6.5.4.Clinical Research Organizations |
7.Regional Outlook (Market Size & Forecast: USD Billion, 2024 – 2030) |
7.1.Global Market Synopsis |
7.2.North America |
7.2.1.North America RNA Analysis Market Outlook |
7.2.1.1.US RNA Analysis Market, By Product & Service |
7.2.1.2.US RNA Analysis Market, By Technology |
7.2.1.3.US RNA Analysis Market, By Application |
7.2.1.4.US RNA Analysis Market, By End-Use |
*Note: Cross-segmentation by segments for each country will be covered as shown above. |
7.2.2.Canada |
7.3.Europe |
7.3.1.Europe RNA Analysis Market Outlook |
7.3.1.1.Germany |
7.3.1.2.UK |
7.3.1.3.France |
7.3.1.4.Spain |
7.3.1.5.Italy |
7.4.Asia-Pacific |
7.4.1.Asia-Pacific RNA Analysis Market Outlook |
7.4.1.1.China |
7.4.1.2.India |
7.4.1.3.Japan |
7.4.1.4.South Korea |
7.4.1.5.Australia |
7.5.Latin America |
7.5.1.Latin America RNA Analysis Market Outlook |
7.5.1.1.Mexico |
7.5.1.2.Brazil |
7.6.Middle East & Africa |
7.6.1.Middle East & Africa RNA Analysis Market Outlook |
7.6.1.1.Saudi Arabia |
7.6.1.2.UAE |
8.Competitive Landscape |
8.1.Market Share Analysis |
8.2.Volume Output Analysis |
8.3.Company Strategy Analysis |
8.4.Competitive Matrix |
9.Company Profiles |
9.1. Agilent Technologies |
9.1.1.Company Synopsis |
9.1.2.Company Financials |
9.1.3.Product/Service Portfolio |
9.1.4.Recent Developments |
9.1.5.Analyst Perception |
*Note: All the companies in the section 9.1 will cover same sub-chapters as above. |
9.2.Basepair |
9.3.BioMérieux |
9.4.Bio-Rad Laboratories |
9.5.Eurofins |
9.6.GenXPro |
9.7.Illumina |
9.8.Promega Corporation |
9.9.Qiagen |
9.10.Roche |
9.11.Thermo Fisher Scientific |
Intent Market Research employs a rigorous methodology to minimize residual errors by carefully defining the scope, validating findings through primary research, and consistently updating our in-house database. This dynamic approach allows us to capture ongoing market fluctuations and adapt to evolving market uncertainties.
The research factors used in our methodology vary depending on the specific market being analyzed. To begin with, we incorporate both demand and supply side information into our model to identify and address market gaps. Additionally, we also employ approaches such as Macro-Indicator Analysis, Factor Analysis, Value Chain-Based Sizing, and forecasting to further increase the accuracy of the numbers and validate the findings.
Our market research methodology utilizes both top-down and bottom-up approaches to segment and estimate quantitative aspects of the market. We also employ multi-perspective analysis, examining the market from distinct viewpoints.